Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of Nolasiban to Increase On-going Pregnancy Rate Following Fresh Single Blastocyst Transfer Resulting From IVF

Trial Profile

A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of Nolasiban to Increase On-going Pregnancy Rate Following Fresh Single Blastocyst Transfer Resulting From IVF

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Nolasiban (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPLANT 4
  • Sponsors ObsEva
  • Most Recent Events

    • 18 Feb 2019 Last checked against ClinicalTrials.gov record.
    • 07 Dec 2018 According to an ObsEva media release, the company has initiated this study and patients are being screened.
    • 28 Nov 2018 According to an ObsEva media release, with a successful outcome of this study, the company is planning a MAA submission in Europe prior to the end of 2019. The study will support a Marketing Authorization Application in Europe, Canada, Russia and other countries such as Switzerland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top